Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ValbiotisXPAR:ALVAL +1.77%52 EV-to-OCF is -3.10 as of Aug. 08, 2026. GuruFocus rates XPAR:ALVAL with a GF Score™ of 52/100 and a GF Value™ of €1.46 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 1,984 Consumer Packaged Goods companies, Valbiotis ranks better than 76.86% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Valbiotis's Enterprise Value is €24.95 Mil.
Valbiotis's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was €-8.04 Mil. Therefore, Valbiotis's EV-to-OCF for today is -3.10.
The historical rank and industry rank for Valbiotis's EV-to-OCF or its related term are showing as below:
XPAR:ALVAL'
s EV-to-OCF Range Over the Past 10 Years
Min: -9.79 Med: -2.31 Max: 19.33
Current: -3.04
During the past 11 years, the highest EV-to-OCF of Valbiotis was 19.33. The lowest was -9.79. And the median was -2.31.
XPAR:ALVAL's EV-to-OCF is ranked better than 76.86% of 1984
companies
in the Consumer Packaged Goods industry
Industry Median: 8.025
vs XPAR:ALVAL: -3.04
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Valbiotis's share price for today is €0.804.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Valbiotis's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.486.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Valbiotis EV-to-OCF Related Terms
Valbiotis EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Valbiotis's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Packaged Foods subindustry, Valbiotis's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Valbiotis EV-to-OCF vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Valbiotis's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Valbiotis's EV-to-OCF falls into.
Valbiotis's current Enterprise Value is €24.95 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Valbiotis's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was €-8.04 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Valbiotis (XPAR:ALVAL) has a EV-to-OCF of -3.10 as of Aug. 08, 2026. According to the industry distribution chart, Valbiotis ranks #459 out of 1984 companies in the Consumer Packaged Goods industry, placing it in the top 23.1%.
Is Valbiotis' EV-to-OCF too high?
Valbiotis' current EV-to-OCF is -3.10. Based on the distribution chart, Valbiotis ranks #459 out of 1984 companies in the Consumer Packaged Goods industry, which is in the top quartile — a strong position relative to peers. Overall, Valbiotis has a GF Score™ of 52/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Valbiotis' EV-to-OCF compare to KHC and GIS?
According to the Consumer Packaged Goods industry distribution chart, Valbiotis ranks #459 out of 1984 companies for EV-to-OCF. This places Valbiotis in the top 23% of its industry — outperforming the majority of peers. The industry median EV-to-OCF is 8.03. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Consumer Packaged Goods company?
The median EV-to-OCF among Consumer Packaged Goods companies is 8.03, based on 1,984 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Consumer Packaged Goods industry, the median EV-to-OCF is 8.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Valbiotis's current EV-to-OCF is -3.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Valbiotis stock overvalued right now?
Based on GuruFocus' analysis, Valbiotis (XPAR:ALVAL) is currently considered Possible Value Trap. The stock's GF Value™ is €1.46, compared to a current price of €0.80 — trading 44.9% below its estimated fair value. The current EV-to-OCF is -3.10. Valbiotis' overall GF Score™ is 52/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Valbiotis (XPAR:ALVAL), the current EV-to-OCF is -3.10 as of Aug. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Valbiotis (XPAR:ALVAL) Overvalued in 2026?
Based on GuruFocus' analysis, Valbiotis stock appears to be undervalued.
The current stock price of €0.80 is trading 44.9% below its estimated GF Value™ of €1.46.
GuruFocus considers Valbiotis to be Possible Value Trap.
Key valuation signals for XPAR:ALVAL:
EV-to-OCF: -3.10
GF Value™: €1.46 vs. price of €0.80 (44.9% below fair value)
No single metric tells the full story. See the XPAR:ALVAL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Valbiotis SA is a research & development company. It is engaged in scientific innovation for preventing and combating metabolic diseases. Valbiotis has adopted an approach, aiming to revolutionize healthcare by developing a new class of Nutrition Health products designed to reduce the risk of metabolic diseases, based on a multi-target approach by the use of plant-based ingredients.
52GF Score
Get the complete analysis for XPAR:ALVAL
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:ALVAL has been successfully added to your 
